Nuformix are excited to announce the provisional US patent filing for its NX017 product. NX017 is a currently marketed drug (2009 global sales > £200m) with significant year-on-year growth both in terms of sales and new indications.
Costly synthesis and formulation requirements combine to make it one of the world’s most expensive drugs. However, Nuformix have successfully reengineered NX017’s solid form to significantly enhance key physical properties.
Such advances can increase bioavailability, enable standard formulation or an alternative release profile, all of which will be crucial for a fast growing and high-cost drug. Nuformix is currently seeking partners to further develop its product portfolio, of which NX017 is the latest validated addition.